Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 8/20 | 0.56 |
| ▸ | LPAR2 | Q9HBW0 | 6/20 | 0.56 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | AKT1 | P31749 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | CDC25A | P30304 | 1/20 | 0.44 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TERT | O14746 | 1/20 | 0.40 |
| ▸ | UCHL3 | P15374 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28846282 | 0.94 | LPAR3 (0.55) | LPAR3LPAR2LPAR1CYP3A4AKT1 | |
| SCHEMBL4451507 | 0.93 | CYP3A4 (0.61) | LPAR3LPAR2LPAR1CYP3A4TSHR | |
| SCHEMBL777909 | 0.91 | LPAR3 (0.56) | LPAR3LPAR2LPAR1CYP3A4AKT1 | |
| SCHEMBL2184249 | 0.91 | LPAR3 (0.56) | LPAR3LPAR2LPAR1CYP3A4AKT1 | |
| SCHEMBL7106488 | 0.88 | LPAR3 (0.59) | LPAR3LPAR2LPAR1CYP3A4AKT1 | |
| SCHEMBL7540607 | 0.88 | LPAR3 (0.59) | LPAR3LPAR2LPAR1CYP3A4AKT1 | |
| SCHEMBL3815174 | 0.88 | LPAR3 (0.59) | LPAR3LPAR2LPAR1CYP3A4AKT1 | |
| SCHEMBL11447220 | 0.88 | LPAR3 (0.59) | LPAR3LPAR2LPAR1CYP3A4AKT1 | |
| SCHEMBL11671731 | 0.88 | LPAR3 (0.59) | LPAR3LPAR2LPAR1CYP3A4AKT1 | |
| SCHEMBL11752839 | 0.88 | LPAR3 (0.59) | LPAR3LPAR2LPAR1CYP3A4AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106848406-B | Nonaqueous electrolyte solution for secondary battery and nonaqueous electrolyte secondary battery | 三菱化学株式会社 | 2020-09-11 | — | — | CN | disclosed |
| CN-111048841-A | Nonaqueous electrolyte solution for secondary battery and nonaqueous electrolyte secondary battery using same | 三菱化学株式会社 | 2020-04-21 | — | — | CN | disclosed |
| CN-105633345-B | Nonaqueous electrolyte solution for secondary battery and nonaqueous electrolyte secondary battery using same | 三菱化学株式会社 | 2020-01-17 | — | — | CN | disclosed |
| US-8835581-B2 | Neutral layer polymer composition for directed self assembly and processes thereof | AZ ELECTRONIC MATERIALS (LUXEMBOURG) S.A.R.L. (LU) | 2014-09-16 | — | — | US | disclosed |
| US-20010025116-A1 | Aluminum salts of phosphinic acids | TICONA GMBH | 2001-09-27 | — | — | US | disclosed |
| US-6211402-B1 | REACTING ESTERS OF PHOSPHINIC ACIDS OR DIPHOSPHINIC ACIDS WITH ALUMINUM HYROXIDE UNDER PRESSURE AT 150 TO 350 DEGREES C. IN PRESENCE OF WATER TO PREPARE HIGH TEMPERATURE MODIFICATION ALUMINUM SALTS | TICONA GMBH (DE) | 2001-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010025116-A1 | Aluminum salts of phosphinic acids | PPA1, PHOSPHO1, AGPS | LPAR3 1176/4885LPAR2 709/4885LPAR1 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.